Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Centessa Pharmaceuticals (CNTA) Other Non-Current Assets: 2022-2025

Historic Other Non-Current Assets for Centessa Pharmaceuticals (CNTA) over the last 4 years, with Sep 2025 value amounting to $1.6 million.

  • Centessa Pharmaceuticals' Other Non-Current Assets fell 28.78% to $1.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.6 million, marking a year-over-year decrease of 28.78%. This contributed to the annual value of $2.0 million for FY2024, which is 19.89% down from last year.
  • Centessa Pharmaceuticals' Other Non-Current Assets amounted to $1.6 million in Q3 2025, which was down 7.62% from $1.7 million recorded in Q2 2025.
  • In the past 5 years, Centessa Pharmaceuticals' Other Non-Current Assets ranged from a high of $6.0 million in Q1 2023 and a low of $619,000 during Q1 2022.
  • For the 3-year period, Centessa Pharmaceuticals' Other Non-Current Assets averaged around $2.4 million, with its median value being $2.1 million (2023).
  • As far as peak fluctuations go, Centessa Pharmaceuticals' Other Non-Current Assets skyrocketed by 875.77% in 2023, and later plummeted by 68.82% in 2024.
  • Centessa Pharmaceuticals' Other Non-Current Assets (Quarterly) stood at $1.9 million in 2022, then spiked by 35.85% to $2.6 million in 2023, then declined by 19.89% to $2.0 million in 2024, then dropped by 28.78% to $1.6 million in 2025.
  • Its last three reported values are $1.6 million in Q3 2025, $1.7 million for Q2 2025, and $1.9 million during Q1 2025.